On Tuesday, Shares of Wendys Co (NASDAQ:WEN), lost -0.09% to $10.57.
Cheeseburger lovers, huddle up! Wendy’s is bringing together aged Gouda and Swiss Gruyere Cheese Sauce with their oven-baked bacon as star players in Wendy’s new Gouda Bacon Cheeseburger. In fact, the cheese in the sandwich has so much swagger, the competition is calling for extra defense.
“Nobody creates a cheeseburger and fries experience like Wendy’s, and our new Gouda Bacon Cheeseburger and Bacon Fondue Fries are no exception,” said Kurt Kane, Wendy’s Chief Concept & Marketing Officer. “Our oven-baked bacon and fresh, never frozen, beef are already famous for being delicious. Now we are combining them with aged Gouda and a Swiss Gruyere cheese sauce that are ready to play their own starring role. Just wait until you see what they can do as a team.”
Wendy’s new Gouda Bacon Cheeseburger starts with a ¼ lb. of 100% pure, fresh, never frozen beef, served hot off the grill. The beef, which is delivered fresh to Wendy’s restaurants two to three times a week, is topped off with a creamy Garlic Aioli, Gouda Cheese and warm Swiss Gruyere Cheese Sauce. Then, three strips of fresh cooked Applewood Smoked Bacon are added, together with red onions, tomato and fresh spring mix – all served on a toasted Brioche Bun. The Gouda Bacon Cheeseburger has a recommended price of $4.99.
The Wendy’s Company, through its auxiliaries, owns and franchises Wendy’s restaurant system. The company is involved in operating, developing, and franchising a system of quick-service restaurants. As of May 26, 2015, its restaurant system comprised about 6,500 franchised and company-operated restaurants worldwide.
Shares of Sabre Corp (NASDAQ:SABR), declined -4.51% to $28.56, during its last trading session.
Sabre Corporation, declared that it has reached a definitive agreement to acquire the Trust Group of Companies, a central reservations, revenue administration and hotel marketing provider with a noteworthy presence in EMEA and Asia Pacific. The acquisition will comprise Trust International, Inn Link and Nexus.
“Acquiring the Trust Group is consistent with our stated aim of building on Sabre Hospitality Solutions’ global leadership position, and this combination will enable us to grow faster,” said Tom Klein, president and chief executive officer of Sabre. “The Trust Group is one of the industry’s most respected brands, and our customers will benefit from our combined expertise and focus on innovation.”
The Trust Group’s global customer base, broad capabilities and unique solutions will allow Sabre to provide a comprehensive SaaS platform, while extending Sabre’s position as the world’s largest central reservations system provider to hotels. Together with the Trust Group, Sabre Hospitality Solutions will serve significantly more hotels than any other central reservations technology provider.
Sabre Corporation provides technology solutions to the travel and tourism industry worldwide. It operates in two segments: Travel Network, and Airline and Hospitality Solutions. The Travel Network segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, counting airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators, with a network of travel buyers comprising online and offline travel agencies, travel administration companies, and corporate travel departments.
Finally, Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), ended its last trade with -1.77% loss, and closed at $17.79.
Celldex Therapeutics, presented mature survival data from the Company’s randomized, double-blind Phase 2 study of RINTEGA(R) (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma (GBM) at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO). The data were presented in a podium presentation by David A. Reardon, M.D., Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School; and President of the Society for Neuro-Oncology, in addition to the lead investigator of the ReACT study. RINTEGA is an investigational EGFRvIII specific therapeutic vaccine and was granted Breakthrough Therapy Designation in February 2014. Patients with recurrent glioblastoma that express the EGFRvIII mutation typically have a worse prognosis than the overall glioblastoma population, counting poor long-term survival (median time from recurrence to death for EGFRvIII-positive patients is 8.7 months1). As formerly stated, the primary endpoint of the study, progression-free survival at six months (PFS6) has been met.
- Mature overall survival (OS) data continue to show a marked benefit [hazard ratio = 0.53 (0.32, 0.88); p=0.0137] with a long-term survival benefit clearly seen in the RINTEGA arm. In May, the Company stated a hazard ratio of 0.57 (0.33, 0.98) (p=0.0386) for OS in the study.
- Nine of 10 patients (one patient lost to follow up) on the RINTEGA arm remain alive since the Company last presented data in May contrast to only two out of five patients on the control arm.
- At two years, the survival rate for RINTEGA patients is 25% as compared to 0% for control patients in the intent to treat (ITT) population, with five patients extending beyond two years.
- Five patients in the RINTEGA arm continue survival follow-up without progression per central review, contrast to only one patient on the control arm.
- A clear advantage continues to be demonstrated across multiple, clinically important endpoints counting overall survival (OS), long-term progression-free survival (PFS), objective response rate (ORR) and need for steroids.
- 33% of patients on the RINTEGA arm who were receiving steroids at baseline were able to stop steroids for six months or longer contrast to none on the control arm.
“The results of the ReACT study change the way we think about glioblastoma—offering patients and their families new hope in the face of one of the most difficult to treat cancers and upending the notion that the brain, masked behind the blood brain barrier, is beyond the reach of the promise of immunotherapy,” said David A. Reardon, M.D. “The long-term survival benefit observed in this study is unprecedented as it is surpassingly rare for patients with highly aggressive, EGFRvIII-positive glioblastoma—even in the newly diagnosed setting—to live beyond two years. Most striking perhaps is that not only are patients living considerably longer, they are also living better, with minimal side effects and a reduced need for steroids. The ReACT data also build considerable anticipation for the ACT IV study in newly-diagnosed glioblastoma as these patients typically present with much stronger immune systems and stand to derive an even greater benefit.”
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The companys lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.